Top 5 Papers
#1
Source: The Lancet Gastroenterology & Hepatology | Authors: Mannucci A, Puzzono M, Marzocca G, Goel A, Ogino S, Syngal S, Yurgelun MB, Gupta S, Cavestro GM, et al. | Published: September 3, 2026
Score: 10/20 — Base 7 (Lancet Gastroenterology & Hepatology — Lancet-family specialty title, scored consistently with the Lancet Digital Health row added 2026-09-03) + meta-analysis (+2) + biomarker-guided/precision (+1). Colleague engagement +0 — the X sweep completed 6/6 handles this morning and returned no KOL post on any paper in this edition.
A PROSPERO-registered systematic review and meta-analysis of 21 studies and 6,925 individuals with colorectal cancer puts the pooled yield of germline multigene panel testing at 15.2% (95% CI 12.8–18.1; I²=84.1%) for any pathogenic or likely pathogenic variant, with high-penetrance variants in 7.9% (5.9–10.5) and high-penetrance CRC-predisposition genes in 5.4% (3.5–8.6). Yield was highest in early-onset disease — 17.7% any and 14.2% high-penetrance below age 50 — but the number that matters for practice is what happens above that threshold: in late-onset CRC the any-variant yield was still 13.0% (10.8–15.7) and high-penetrance 6.5% (4.4–9.5). Modelling put the age at which high-penetrance yield finally falls below 5% at 67 years (95% CI 59–75), well beyond the cutoffs most testing criteria still use. Neither panel size nor publication year affected yield, which argues the result is not an artifact of newer and larger panels. Risk of bias was low in 10 studies, moderate in 9 and high in 2, and heterogeneity was substantial.
Post angle: Every criterion that stops germline panel testing at 50 is leaving high-penetrance carriers undiagnosed — this meta-analysis puts the >5% yield threshold at age 67. #GIOnc #CRC #Lynch #PrecisionMedicine
#2
Source: Endoscopy — European Society of Gastrointestinal Endoscopy | Authors: Lemmers A, Tringali A, Teles de Campos S, Triantafyllou K, et al. (ESGE, multinational) | Published: September 3, 2026
Score: 10/20 — Base 7 (major society clinical practice guideline — scored on the NCCN guideline row, the closest analogue in the table; Endoscopy had no row of its own) + new standard of care (+3). No study-type bonus: a guideline is not a trial. Colleague engagement +0 (sweep completed 6/6; no KOL posts on this paper).
ESGE's new guideline sets 13 formal recommendations across benign strictures (post-cholecystectomy, post-transplant anastomotic, chronic pancreatitis, PSC), distal malignant biliary obstruction, hilar malignant strictures, and failed or unfeasible ERCP. For oncology practice the malignant recommendations are the operative ones: a 10-mm self-expandable metal stent is preferred for preoperative and neoadjuvant drainage of extrahepatic malignant biliary obstruction, endoscopic drainage is preferred over surgical or percutaneous approaches in inoperable extrahepatic disease, and ERCP is preferred over percutaneous transhepatic biliary drainage for preoperative drainage of hilar obstruction. In Bismuth II–IV hilar strictures the guideline sets an explicit volumetric target — drain more than 50%, and ideally at least 70%, of viable non-atrophic liver volume. After failed ERCP, EUS-guided biliary drainage is preferred over PTBD. Taken together these are the recommendations that govern how a patient with pancreatic or biliary cancer gets decompressed before systemic therapy begins.
Post angle: New ESGE biliary stricture guideline: 10-mm SEMS for preoperative and neoadjuvant drainage, EUS-BD over PTBD after failed ERCP, and an explicit ≥70% viable-liver-volume drainage target in Bismuth II–IV. Worth reading before your next neoadjuvant case. #GIOnc #Cholangiocarcinoma #PDAC
#3
Source: British Journal of Cancer | Authors: Hirano H, Yamada Y, Boku N, Kurokawa Y, Terashima M, Yoshikawa T, et al. (JCOG) | Published: September 4, 2026
Score: 9/20 — Base 6 (British Journal of Cancer) + ancillary biomarker analysis of a randomised Phase III trial (+2 — scored at the Phase II level rather than the full +3, because this is a correlative analysis and not the primary trial report) + biomarker-guided/precision (+1). Colleague engagement +0 (sweep completed 6/6; no KOL posts on this paper).
This ancillary analysis of the randomised Phase III JCOG1013 trial scored PD-L1 with the Dako 28-8 pharmDx assay in 540 of the 741 enrolled patients, all of whom received chemotherapy without an immune checkpoint inhibitor. The two scoring systems diverged. CPS ≥5 — the threshold that drives first-line ICI eligibility in gastric cancer — was not associated with overall survival (HR 0.86, 95% CI 0.71–1.04, p=0.127) or progression-free survival (HR 0.92, 0.77–1.11, p=0.392). TPS ≥1% was associated with both: OS HR 0.78 (0.62–0.97, p=0.028) and PFS HR 0.76 (0.62–0.94, p=0.012). The authors conclude that TPS ≥1% is an independent favourable prognostic factor on chemotherapy alone. The essential caveat is the population: because nobody here received immunotherapy, the finding is prognostic and not predictive of ICI benefit. It says something about tumour biology, not about who should be offered a checkpoint inhibitor.
Post angle: In 540 patients on chemotherapy alone, PD-L1 CPS ≥5 said nothing about survival — but TPS ≥1% did (OS HR 0.78, p=0.028). A reminder that CPS and TPS are not interchangeable, and that prognostic is not predictive. #GIOnc #GastricCancer #Biomarkers
#4
Source: American Journal of Gastroenterology | Authors: Garg SK, Hintz CF, Ebner DW, Kisiel JB, Chaudhary R (Mayo Clinic) | Published: September 3, 2026
Score: 8/20 — Base 6 (American Journal of Gastroenterology — society flagship, scored at the level the table gives British Journal of Cancer and Clinical Cancer Research; AJG had no row of its own) + retrospective real-world program (+1) + biomarker-guided/precision (+1, molecular screening assay). Colleague engagement +0 (sweep completed 6/6; no KOL posts on this paper).
Mayo's decade-long program covers 148,624 multi-target stool DNA tests in 110,410 individuals between September 2014 and July 2025, with a 13.6% positivity rate. The diagnostic yield after a positive test was strong — advanced adenoma in 30.7% and adenocarcinoma in 1.3%, with an adenoma detection rate above 50% that exceeded society benchmarks and rose over the decade. The failure sits downstream of the assay: of 19,506 positive results, only 65.1% led to a completed colonoscopy within 12 months (median 82 days), and longer intervals to colonoscopy were associated with higher advanced adenoma rates (trend p=0.001). Adherence after a negative test was worse still, with only 35.3% re-screened within three years — and colonoscopy performed within three years of a negative mt-sDNA still found adenomas or serrated lesions in 45.2%, advanced adenoma in 9.3% and cancer in 0.5%. Endpoints were extracted from free-text reports by a validated large-language-model pipeline, which is worth naming as a methodological caveat rather than buried in the methods.
Post angle: A screening test only works if the loop closes. 148,624 mt-sDNA tests at Mayo: yield after a positive result was excellent, but only 65% got their colonoscopy within a year and just 35% re-screened after a negative. The weak link is not the assay. #GIOnc #CRC #Screening
#5
Source: Gastroenterology | Authors: Everhov ÅH, Kristjánsson K, Ludvigsson JF, Halfvarson J, Nordenvall C, Sorensen HT, Askling J, Olén O, et al. | Published: September 2, 2026
Score: 8/20 — Base 7 (Gastroenterology — the flagship GI specialty journal, scored at the level the table gives Annals of Oncology and JAMA Oncology; it had no row of its own) + nationwide register-based real-world cohort (+1). No clinical-impact bonus: the paper reframes risk stratification rather than establishing a new standard. Colleague engagement +0 (sweep completed 6/6; no KOL posts on this paper).
This nationwide Swedish register study followed 124,387 patients with IBD (1,882 CRC events, incidence rate 1.17 per 1,000 person-years) against 1,213,641 matched general-population comparators (14,177 events, 0.88 per 1,000 person-years) from 1996 to 2023, with a median 11 years of follow-up. The largest excess came from having two or more affected first-degree relatives: 2.69 additional CRC cases per 1,000 person-years (95% CI 0.60–4.78) versus no family history. What did not hold up was the early-onset heredity signal that current surveillance guidelines lean on — a relative diagnosed before age 50 conferred only 0.42 additional cases per 1,000 person-years (95% CI −0.47 to 1.31), an interval that crosses zero. On the absolute scale family history acted much the same in IBD as in the comparator population; the relative effect looks weaker in IBD only because baseline risk is already elevated. The authors explicitly question whether guidelines should prioritise the number of affected relatives over the age at which they were diagnosed.
Post angle: Swedish nationwide data on 124,387 IBD patients: the CRC risk signal came from having two or more affected first-degree relatives, not from a relative diagnosed under 50. Current guidelines weight it the other way round. #GIOnc #CRC #IBD
Additional Papers of Interest
-
Nature Medicine — in 53 patients with mild-to-moderate ulcerative colitis or Crohn's disease, fluconazole but not nystatin reduced intestinal Candida burden, expanded SCFA-producing taxa and improved disease activity over 8 weeks. This is the week's only other Tier-1 paper touching the GI tract; it sits here rather than in the Top 5 because it is gastroenterology rather than oncology, though it pairs directly with the IBD colorectal cancer risk study above.
-
Journal of Clinical Oncology — a commentary on what the second-line daraxonrasib signal does and does not license in the first-line setting. Included to satisfy the Tier-1 safety net; it is opinion rather than new data, and daraxonrasib has featured in 18 prior editions including its FDA approval on August 27.
-
ESMO Gastrointestinal Oncology — a negative Phase II. ORR was 7.5% (3/40) against a 25% target, with median PFS 1.8 months and median OS 5.9 months among 47 treated patients and grade ≥3 adverse events in 60%. PD-L1 did not predict benefit, although one responder with a CPS of 85 was alive three years after progression.
-
ESMO Gastrointestinal Oncology — across four age bands, APC rose from 49.4% in patients aged 18–29 to 75.3% in those 50 and over (OR 3.74), SMAD4 was twice as common in the youngest band (31.6%, OR 2.03), and POLE peaked at 10.7% in the 30–39 group (OR 1.96 versus those over 40) — the immunotherapy-relevant signal, in the age band where it is least expected.
-
Nature Communications — a single-cell multi-omics atlas of 14 HCC patients treated with neoadjuvant anti-PD-1 (NCT06571396) plus 60 external cases, identifying lipid-associated macrophage–mediated immunosuppression as a determinant of resistance.
-
Nature Communications — preclinical work showing that Lin28b in cancer-associated fibroblasts binds and degrades STING mRNA, suppressing type-I interferon signalling; CAF-specific Lin28b loss reactivates the cGAS–STING–IFN axis. No patient endpoints yet.
Back to all digests